Metachlorophenylpiperazine (mCPP): A new designer drug;La métachlorophénylpipérazine (mCPP): Une nouvelle drogue de synthèse

Therapie

Volumn 61, Issue 6, 2006, Pages 523-530

  Lecompte, Yannick ^a   Evrard, Isabelle ^b   Arditti, Jocelyne ^c  

^a INSTITUT GÉOGRAPHIQUE NATIONAL   (France)

^b Observatoire Français des Drogues et des Toxicomanies OFDT   (France)

^c Centre d'Evaluation et d'Information Sur la Pharmacodépendance   (France)

Author keywords

Designer drug; mCPP; Metachlorophenylpiperazine

Indexed keywords

AMPHETAMINE; DESIGNER DRUG; ILLICIT DRUG; METACHLOROPHENYLPIPERAZINE; PSYCHOTROPIC AGENT; SEROTONIN RECEPTOR; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG; (3 CHLOROPHENYL)PIPERAZINE; 1-(3-CHLOROPHENYL)PIPERAZINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; PIPERAZINE DERIVATIVE; SEROTONIN AGONIST; STREET DRUG;

CONFERENCE PAPER; DRUG EFFECT; DRUG INTOXICATION; DRUG USE; ENDOCRINE SYSTEM; EUROPE; FRANCE; MARKET; MENTAL DISEASE; NEUROLOGY; PATHOLOGY; PHARMACODYNAMICS; PRIORITY JOURNAL; REGULATORY MECHANISM; RISK; RISK ASSESSMENT; RISK FACTOR; ARTICLE; DRUG LEGISLATION; HUMAN; PSYCHOLOGICAL ASPECT; PSYCHOSIS;

DESIGNER DRUGS; EUROPE; FRANCE; HUMANS; LEGISLATION, DRUG; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; PIPERAZINES; PSYCHOSES, SUBSTANCE-INDUCED; RECEPTORS, SEROTONIN; SEROTONIN AGONISTS; STREET DRUGS;

EID: 33947720724     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: 10.2515/therapie:2006093     Document Type: Conference Paper

References (56)

1. De Boer D, Bosman IJ, Hidvégi E, et al. Piperazine-like compounds: a new group of designer drugs-of-abuse on the European market. Forensic Sci Int 2001; 121: 47-56
2. Baumann MH, Clark RD, Budzynski AG, et al. N-substituted piperazines abused by humans mimic the molecular mechanism of 3,4-methylenedioxymethamphetamine (MDMA. or "ecstasy"). Neuropsychopharmacology 2005; 30: 550-60
3. Observatoire français des drogues et des toxicomanies. M-chlorophénylpipérazine (mCPP), nouvelle identification. Note d'information du 14 mars 2006: 1-5
4. European Police Office, European monitoring centre on drugs and drug addiction. Europol-EMCDDA joint report on a new psychoactive substance: 1-(3-chlorophenyl)piperazine (mCPP). novembre 2005: 1-14
5. Bossong MG, Van Dijk JP, Niesink RJM. Methylone and mCPP, two new drugs of abuse? Addict Biol 2005; 10(4): 321-3
6. Samanin R, Mennini T, et al. Chlorophenylpiperazine: a central serotonin agonist causing powerful anorexia in rats. Naunyn Schmiedebergs Arch Pharmacol 1979; 308(2): 159-63
7. Murphy DL, Lesch KP, Aulakh CS, et al. Serotonin-selective arylpiperazines with neuroendocrine, behavioral, temperature, and cardiovascular effects in humans. Pharmacol Rev 1991; 43(4): 527-45
8. Rotzinger S, Fang J, Bake GB. Trazodone is metabolized to m-chlorophenylpiperazine by CYP3A4 from human sources. Drug Metab Dispos 1998; 26(6): 572-5
9. Mihara K, Yasui-Furukori N, Kondo T. et al. Relationship between plasma concentrations of trazodone and its active metabolite, m-chlorophenylpiperazine, and its clinical effect in depressed patients. Ther Drug Monit 2002; 24: 563-6
10. Maes M. Westenberg H, Vandoolaeghe E, et al. Effects of trazodone and fluoxetine in the treatment of major depression: therapeutic pharmacokinetic and pharmacodynamic interactions through formation of metachlorophenylpiperazine. J Clin Psychopharmacol 1997; 17(5): 358-64
11. Erowid. mCPP. http://www.erowid.org/chemicals/mcpp/mcpp.shtml
12. Observatoire belge des drogues et toxicomanies. Circulation du mCPP dans les pillules dites «arc-en-ciel». Message d'alerte précoce du 26 juillet 2005 : 1-3
13. Baumann MH, Ayestas MA, Dersch CM, et al. 1-(m-chlorophenyl) piperazine (mCPP) in vivo serotonin release from long-term serotonin depletion in rat brain. Neuropsychopharmacology 2001 ; 24(5): 492-501
14. Morton J. Ecstasy: pharmacology and neurotoxicity. Curr Opin Pharmacol 2005; 5(1): 79-86
15. Hamik A, Peroutka SJ. 1-(m-chlorophenyl)piperazine (mCPP) interactions with neurotransmitter receptors in human brain. Biol Psychiatry 1989; 25: 569-75
16. 2C receptors in CHO-K1 cells. Br J Pharmacol 1999; 128: 13-20
17. Kahn RS, Wetzler S. M-chlorophenylpiperazine as a probe of serotonin function. Biol Psychiatry 1991; 30: 1139-66
18. Baumann MH, Mash DC, Staley JK. The serotonin agonist m-chlorophenylpiperazine (mCPP) binds to serotonin transporter sites in human brain. Neuroreport 1995; 6(16): 2150-2
19. Owens MJ, Morgan WN, Plott SJ, et al. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther 1997; 283(3): 1305-22
20. 7 receptor. Eur J Pharmacol 2000; 396: 1-8
21. Baumann MH, Rutter JJ, Auerbach SB. Intravenous administration of the serotonin agonist m-chlorophenylpiperazine (mCPP) increases extracellular serotonin in the diencephalon of awake rats. Neuropharmacology 1993; 32(12): 1381-6
22. Rothman RB, Baumann MH. Therapeutic and adverse actions of serotonin transporter substrates. Pharmacol Ther 2002; 95: 73-88
23. Feuchtl A, Bagli M, Stephan R, et al. Pharmacokinetics of m-chlorophenylpiperazine after intravenous and oral administration in healthy male volunteers: implication for the pharmacodynamic profile. Pharmacopsychiatry 2004; 37: 180-8
24. Staack RF, Maurer HH. Piperazine-derived designer drug 1-(3-chlorophenyl)piperazine (mCPP): GC-MS studies on its metabolism and its toxicological detection in rat urine including analytical differentiation from its precursor drugs trazodone and nefazodone. J Anal Toxicol 2003; 27: 560-8
25. Maurer HH, Kraemer T, Springer D, et al. Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (ecstasy), piperazine, and pyrrolidinophenone types. Ther Drug Monit 2004; 26(2): 127-31
26. Rotzinger S, Fang J, Coutts RT, et al. Human CYP2D6 and metabolism of m-chlorophenylpiperazine. Biol Psychiatry 1998; 44: 1185-91
27. Kahn RS, Wetzler S, Asnis GM, et al. Effects of m-chlorophenylpiperazine in normal subjects: a dose-response study. Psychopharmacol 1990; 100: 339-44
28. Gijsman HJ, Van Gerven JMA, Tieleman MC, et al. Pharmacokinetic and pharmacodynamic profile of oral and intravenous meta-chlorophenylpiperazine in healthy volunteers. J Clin Psychopharmacol 1998; 18(4): 289-95
29. Ghaziuddin N, WelchK, Greden J. Central serotoninergic effects of m-chlorophenylpiperazine (mCPP) among normal control adolescents. Neuropsychopharmacology 2003; 28: 133-9
30. Benjamin J, Greenberg BD, Murphy DL. Daily administration of m-chlorophenylpiperazine to healthy human volunteers rapidly attenuates many of its behavioral, hormonal, cardiovascular and temperature effects. Psychopharmacol 1996; 127: 140-9
31. Silverstone PH, Rue JE, Franklin M, et al. The effects of administration of mCPP on psychological, cognitive, cardiovascular, hormonal and MHPG measurements in humans volunteers. Int Clin Psychopharmacol 1994; 9: 173-8
32. 2A receptor function by chronic administration of selective serotonin reuptake inhibitors. Brain Res 2006; 1067(1): 164-9
33. 2C receptor activation by m-chlorophenylpiperazine detected in humans with fMRI. Neuroreport 2002; 13(12): 1547-51
34. Kalus O, Wetzler S, Kahn RS, et al. A dose-response study of intravenous m-chlorophenylpiperazine in normal subjects. Psychopharmacol 1992; 106: 388-90
35. Leone M, Attanasio A, Croci D, et al. The serotonergic agent m-chlorophenylpiperazine induces migraine attacks: a controlled study. Neurology 2000; 55: 136-9
36. Charney DS, Woods SW, Goodman WK, et al. Serotonin function in anxiety: effects of the serotonin agonist mCPP in panic disorder patients and healthy subjects. Psychopharmacol 1987; 92: 14-24
37. Gatch MB. Discriminative stimulus effects of m-chlorophenylpiperazine as a model of the role of serotonin receptors in anxiety. Life Sci 2003; 73: 1347-67
38. Simeon D, Hollander E, Stein DJ, et al. Induction of depersonalization by the serotonin agonist meta- chlorophenylpiperazine. Psychiatry Res 1995; 58: 161-4
39. Hollander E, Stein DJ, DeCaria C, et al. Serotoninergic sensitivity in borderline personality disorder: preliminary findings. Am J Psychiatry 1994; 151: 277-80
40. Wetzler S, Asnis G, DeLecuona J, et al. Serotonin function in panic disorder: intravenous administration of meta-chlorophenylpiperazine. Psychiatry Res 1996;64:77-82
41. Erzegovesi S, Martucci L, Henin M, et al. Low versus standard dose mCPP challenge in obsessive-compulsive patients. Psychopharmacol 2001; 24(1): 31-6
42. Tancer ME, Johanson CE. Subjective effects of MDMA and mCPP: a human dose run-up study. Biol psychiatry 2000; 47: 67S
43. Tancer ME, Johanson CE. Reinforcing, subjective, and physiological effects of MDMA in humans: a comparison with d-amphetamine and mCPP. Drug Alcohol Depend 2003; 72: 33-44
44. Tancer ME, Johanson CE. The subjective effects of MDMA and mCPP in moderate MDMA users. Drug Alcohol Depend 2001; 65: 97-101
45. Johanson CE, Kilbey M, Gatchalian K, et al. Discriminative stimulus effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans trained to discriminative among d-amphetamine, meta-chlorophenylpiperazine and placebo. Drug Alcohol Depend 2006; 81(1): 27-36
46. Klaassen T, Ho Pian KL, Westenberg HGM, et al. Serotonin syndrome after challenge with the 5-HT agonist meta- chlorophenylpiperazine. Psychiatry Res 1998;79:207-12
47. Verstraete A, De Paepe P. A case of m-chlorophenylpiperazine poisoning. Troisièmes journées internationales de toxicologie hospitalière. Liège, 24 et 25 novembre 2005: 12
48. Kupiec TC, Raj V, Vu N. Pharmacogenomics for the forensic toxicologist. J Anal Toxicol 2006; 30: 65-71
49. Borg S, Öhman I. Antidepressant drugs. In Aronson JK, editors. Meyler's side effects of drugs. 40th ed. New-York: Elsevier, 2000: 33-85
50. Ulrichsen J, Partilla JS, Dax EM. Long-term administration of m-chlorophenylpiperazine (mCPP) to rats induces changes in serotonin receptor binding, dopamine levels and locomotor activity without altering prolactin and corticosterone secretion. Psychopharmacol 1992; 107: 229-35
51. Vickers SP, Easton N, Webster LJ, et al. Oral administration of the 5-HT2C receptor agonist, mCPP, reduces body weight gain in rats over 28 days as a result of maintained hypophagia. Psychopharmacol 2003; 167(3): 274-80
52. McCann UD, Eligulashvili V, Mertl M, et al. Altered neuroendocrine and behavioural responses to m-chlorophenylpiperazine in 3,4- methylenedioxymethamphetamine (MDMA) users. Psychopharmacol 1999; 147: 56-65
53. Buydens-Branchey L, Branchey M, Fergeson P, et al. The meta-chlorophenylpiperazine challenge test in cocaine addicts: hormonal and psychological responses. Biol Psychiatry 1997; 41: 1071-86
54. Buydens-Branchey L, Branchey M, Fergeson P, et al. Hormonal, psychological, and alcohol craving changes after m-chlorophenylpiperazine administration in alcoholics. Alcohol Clin Exp Res 1997; 21(2): 220-7
55. EMCDDA-Europol annual report on the implementation of Council decision 2005/387/JHA
56. Conseil de l'Union Européenne. Décision 2005/387/JAI du 10 mai 2005 relative à l'échange d'informations, à l'évaluation des risques et au contrôle des nouvelles substances psychoactives. Journal officiel de l'Union européenne du 20 mai 2005; L127: 32-36